Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief Executive Officer Margaret Foti, PhD, MD (hc). Since then, we’ve had the privilege of reporting on some significant progress against cancer, including the rise of immunotherapy and precision medicine. We’ve also covered cutting-edge research presented at AACR Annual Meetings in Philadelphia, New Orleans, and Washington, D.C.
Cancer Research Catalyst has chronicled the AACR’s efforts in influencing cancer science policy and providing powerful advocacy for federal funding of biomedical research. We gave readers a front-row seat as former Vice President Joe Biden told Annual Meeting attendees that “this is no time to stop the momentum.” Along the way, we’ve introduced our readers to AACR members on the front lines of cancer research, as well as survivors who have benefited from that research.
The past year provided an abundance of content, from groundbreaking basic cancer research advances, to a wave of new drug approvals, to early results from our data-sharing initiative, AACR Project GENIE. As always, immunotherapy remains a hot topic, as indicated by a look at our 10 most-read stories from the past year.
In the coming year, we’ll continue to write about the latest developments across the cancer continuum. We’d love to hear what you’re interested in reading, and we encourage you to use the blog as a platform to engage with one another, interact with AACR leadership and staff, and provide feedback. You can leave a comment on any post; connect with us on Facebook, Twitter, or LinkedIn; or email blog@aacr.org.
Can We Treat Colorectal Cancer with Immunotherapy?
Why Does Immunotherapy Not Benefit Everyone Long Term?
Can a Serum Biomarker Predict Response to Immunotherapy?
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Get the latest blog posts delivered to your inbox.
